Резолюция заседания экспертов рабочей группы Российской Противоэпилептической Лиги

1. Global burden of epilepsy and the need for coordinated action at the country level to address its health, social and public knowledge implications, WHA Resolution, 26 May 2015 http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_R20-ru.pdf , dostup dekabr' 2015.

2. Schiller Y., Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology. 2008; 70: 54-65.

3. Kwan P. et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 1: 1069-77.

4. Guekht A., Hauser W.A., Milchakova L., Churillin Y., Shpak A., Gusev E.The epidemiology of epilepsy in the Russian Federation. Epilepsy Res. 2010 Dec; 92 (2-3): 209-18.

5. Rudakova I.G., Vlasov P.N., Lipatova L.V., Voronkova K.V. Lacosamide (vimpat). Prospects for clinical application. Zhurnal nevrologii i psixiatrii im. S.S. Korsakova. 2017; 9: 147-152. (in Russ). https://doi.org/10.17116/jnevro201711791147-152.

6. Curia G., Biagini G., Perucca E. et al. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009; 23 (7): 555-568.

7. Errington A.C., Stohr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008; 73 (1): 157-169.

8. Panayiotopoulos C. P. Principles of therapy in the epilepsies. A Clinical Guide to Epileptic Syndromes and their Treatment. Springer London. 2010; 173-235.

9. Baulac M., Rosenow F., Toledo M., Terada K., Li T., De Backer M., Werhahn K. J., Brock M. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017; 16: 43-54.

10. Brodie M.J. et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013; 54: 11-27.

11. Vlasov P.N., Kamelkova E.G., Drozzhina F.R. Efficacy and tolerance of intravenous lacosamide in urgent neurological situations. Neurology, Neuropsychiatry, Psychosomatics. 2012; 4 (1S): 60-63. (In Russ.) https://doi.org/10.14412/2074-2711-2012-2501.

12. Vlasov P.N. Intravenous Antiepileptic Drugs in Russia. Neurology, Neuropsychiatry, Psychosomatics. 2014; 6 (1S): 48-53. (In Russ.) https://doi.org/10.14412/2074-2711-2014-1S-48-53.

13. Vlasov P.N., Shaxabasova Z.S., Filatova N.V. Epilepsy first occured in elderly patients: diagnosis, differential diagnosis, therapy. Farmateka. 2010; 7: 40-47. (In Russ.). eLIBRARY ID: 15103356.

14. Karlov V.A., Gext A.B., Guzeva V.I., Lipatova L.V., Bazilevich S.N., Mkrtchan V.R., Vlasov P.N., Zhidkova I.A., Muxin K.Yu., Petruxin A.S., Lebedeva A.V. Algorithms of mono- and polytherapy in clinical epileptology. Zhurnal nevrologii i psixiatrii im. S.S. Korsakova. 2016; 7: 120-129. (In Russ.). eLIBRARY ID: 26469142.

15. Helmstaedter C., Witt J.A. The longer-term cognitive effects of ajunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Epilepcy & Behavior. 2013; 26: 182-187. https://doi.org/10.1016/j.yebeh.2012.11.052.

16. Moseley B.D., Cole D., Iwuora O., Strawn J.R., Privitera M. The effects of lacosamide on depression and anxiety in patients with epilepsy. Epilepsy Research. 2015; 110: 115-118. https://doi.org/10.1016/j.eplepsyres.2014.1012.1007.